Niche pain relief Target clinics and pain management centers specializing in oncologic and neuropathic pain that are seeking non-pharmacologic and non-invasive treatment options to expand their offering and differentiate from traditional pharmacotherapy.

Non-invasive differentiation Position CPR-T as a cutting-edge alternative to opioids and implanted devices, highlighting rapid, repeatable pain reduction and potential to reduce reliance on narcotics for high-intensity pain patients.

Clinical validation Leverage the association with Professor Giuseppe Marineo and Delta R&D to support credibility; pursue partnerships with academic medical centers for clinical studies or case series to strengthen evidence for broader adoption.

SMB to mid-market fit With a small team now, target independent clinics and regional pain practices that can scale adoption through streamlined training and managed service delivery, offering a high-value, low-headcount implant for their portfolio.

Growth through partnerships Explore strategic alliances with large health systems and hospitals that operate large pain management or cancer centers, aiming to integrate CPR-T into existing multidisciplinary care pathways to access higher patient volumes.